Zhu Z^#, Sun J^#, Xu W^#, Zeng Q, Feng H, Zang L, He Y, He X, Sheng N, Ren X, Liu G, Huang H, Huang R*, Yan J*. MGAT4A/Galectin-9-driven N-Glycosylation aberration as a promoting mechanism for poor prognosis of endometrial cancer with TP53 mutation. Adv Sci. (Weinh). 2024 Nov 11:e2409764. doi: 10.1002/advs.202409764. Online ahead of print. link

Li M^#, Cui Y^#, Qi Q, Liu J, Li J, Huang G, Yang J, Sun J, Ma Z, Liang S, Zhang D, Jiang J, Zhu R*, Liu Q*, Huang R*, Yan J*. SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1. Theranostics 2024; Oct 7;14(17):6543-6559. doi: 10.7150/thno.101575. link

Zhuang J^#, Shen L^#, Li M^#, Sun J, Hao J, Li J, Zhu Z, Ge S, Zhang D, Guo H*, Huang R*, Yan J*. Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res. 2023 May 15;83(10):1611-1627. doi: 10.1158/0008-5472.CAN-22-2213. link

Liu J^#, Li M^#, Wu J^#, Qi Q, Li Y, Wang S, Liang S, Zhang Y, Zhu Z, Huang R*, Yan J*, Zhu R*. Identification of ST3GAL5 as a prognostics biomarker correlating with CD8+ T cell exhaustion in clear cell renal cell carcinoma. Front. Immunol. 2022 Sep 12;13:979605 doi: 10.3389/fimmu.2022.979605. link

Yang L^#, Sun J^#, Li M, Long Y, Zhang D, Guo H*, Huang R*, Yan J*. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness. Cancer Res. 2021 Nov 15;81(22):5720-5732. doi: 10.1158/0008-5472.CAN-21-0646. link 

Huang Z^#, Yan YL^#, Zhu Z^#, Liu J, He X, Dalangood S, Li M, Tan M, Cai J, Tang P, Huang R, Shen B, Huang R*, Shen B*, Yan J*. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell Death Dis. 2021 May 25;12(6):537. doi:10.1038/s41419-021-03819-0. link 

Dalangood S^#, Zhu Z^#, Ma Z, Li J, Zeng Q, Yan Y, Shen B, Yan J*, Huang R*. Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics 2020 Aug 8;10(22):10078-10091. doi:10.7150/thno.48711. link 

Huang X^#, Zhu H^#, Gao Z, Li J, Zhuang J, Dong Y, Shen B, Li M, Zhou H, Guo H*, Huang R*, Yan J*. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J. Biol. Chem. 2018 May 4;293(18):6693. doi:10.1074/jbc.RA118.001689. link 

Chang C^#, Liu J, He W, Qu M, Huang X, Deng Y, Shen L, Zhao X, Guo H, Jiang J, Fu XY, Huang R, Zhang D, Yan J*. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression. Oncogene 2018 Jan 25;37(4):415-26. doi:10.1038/onc.2017.332. link 

Zhuang J^#, Shen L^#, Yang L, Huang X, Lu Q, Cui Y, Zheng X, Zhao X, Zhang D, Huang R, Guo H*, Yan J*. TGFβ1 promotes gemcitabine resistance through regulating the lncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics 2017 Jul 22;7(12):3053-3067. doi:10.7150/thno.19542. link 

Han Y^#, Huang W^#, Liu J, Liu D, Cui Y, Huang R, Yan J*, Lei M*. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. Theranostics 2017 Apr 20;7(7):1914-1927. doi:10.7150/thno.17852. link 

Zhao W^#, Chang C, Cui Y, Zhao X, Yang J, Shen L, Zhou J, Hou Z, Zhang Z, Ye C, Hasenmayer D, Perkins R, Huang X, Yao X, Yu L, Huang R, Zhang D, Guo H*, Yan J*. Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α. J. Biol. Chem. 2014 Apr 18;289(16):11219-11229. doi: 10.1074/jbc.M113.535989. link 

Yan J^#, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY, Tsai MJ*. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008 Jul 1;68(13):5460-8. doi: 10.1158/0008-5472.CAN-08-0955. link 

Yan J^#, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ*. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006 Nov 15;66(22):11039-46. doi: 10.1158/0008-5472.CAN-06-2442. link 

Yan J^#, Yu Y, Wang N, Chang Y, Ying H, Liu W, He J, Li S, Jiang W, Li Y, Liu H, Wang H, Xu Y*. LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 2004 Mar 11;23(10):1939-49. doi: 10.1038/sj.onc.1207306. link 

Yan J^#, Ying H, Gu F, He J, Li YL, Liu HM, Xu YH*. Cloning and characterization of a mouse liver-specific gene mfrep-1, up-regulated in liver regeneration. Cell Res. 2002 Dec;12(5-6):353-61. doi: 10.1038/sj.cr.7290137. link 

Yan J^#, Tsai SY, and Tsai MJ*. A central role of SRC-3/AIB1 in tumorigenesis. In: Kumar R and O’Malley BW, eds. Nuclear receptor coregulators and human diseases. Singapore: World Scientific; 2008. p.219-241.

Yan J^#, Tsai SY, Tsai MJ*. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharm. Sin. 2006 Apr;27(4):387-94. doi: 10.1111/j.1745-7254.2006.00315.x. (Invited Review)

Lu Y^#, Lin Y, Zhang X, Yan J, Kong Z, Zhang L, Wang C, Huang Y, Zhao S*, Li Y*. LncRNA-AP006284.1 promotes prostate cancer cell growth and motility by forming RNA-DNA triplexes and recruiting GNL3/SFPQ complex to facilitate RASSF7 transcription. Genes Dis. 2022 Apr 26;10(2):317-320. doi: 10.1016/j.gendis.2022.04.005.

Zhu H^#, Ren S^#, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y*, Zhang R*. SPOP E3 ubiquitin ligase adaptor promotes cellular senescence by degrading the SENP7 deSUMOylase. Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083.

An J^#, Ren S^#, Murphy SJ^#, Dalangood S^#, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J^Ɨ, Sun Y*^,Ɨ, Huang H*^,Ɨ. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 2015 Sep 17;59(6):904-16. doi: 10.1016/j.molcel.2015.07.025. 

Kinkade CW^#, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C*. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764. 

Ayala G^#,*, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin. Cancer Res. 2008 Nov 15;14(22):7511-8. doi: 10.1158/1078-0432.CCR-08-0839.